For those with hypermobility and EDS specifically, Id flag the following as the minimum due diligence before starting these medications: A thorough GI history and ideally gastric emptying assessment if theres any existing dysmotility Baseline muscle mass measurement (DEXA or similar) given the sarcopenia risk A clear plan for high-protein diet and resistance-based exercise to mitigate muscle loss Baseline bone density if theres any existing concern Consideration of the nutritional picture specific to hypermobility, since these drugs can affect appetite and nutrient absorption A conversation specifically about MCAS if thats a feature of your presentation The medication options for hypermobility and EDS are limited and often unsatisfying, and its entirely understandable why people are looking at something new with genuine curiosity
It says a headache warrants evaluation if it continues beyond week six, gets worse as the dose escalates, or arrives alongside vision changes, severe nausea, or chest discomfort
As of April 2026, Wegovy is available in all doses, and the FDA has declared its previous shortage as resolved
One possibility is that GLP-1R endocytosis is required for agonist uptake by the brain via hypothalamic tanycytes, as described for leptin 65
There are clear situations where it makes more sense than tirzepatide, and dismissing it entirely because tirzepatide produces more weight loss would be a mistake
Stellwagen D, Beattie EC, Seo JY, Malenka RC (2005)
